TY - JOUR
T1 - Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia inJapan
AU - Yamamoto, Yoshihiro
AU - Watanabe, Akira
AU - Goto, Hajime
AU - Matsushima, Toshiharu
AU - Abe, Shosaku
AU - Aoki, Nobuki
AU - Shimokata, Kaoru
AU - Mikasa, Keiichi
AU - Niki, Yoshihito
AU - Kohno, Shigeru
N1 - Funding Information:
Conflict of interest Dr. Watanabe has received honoraria from Astellas, Shionogi, Daiichi Sankyo, Taisho Toyama, Dainippon Sumitomo, and Pfizer Japan; manuscript fees from Kyowa Kikaku; donations from Astellas and Daiichi Sankyo; endowed chair from KYORIN, Shionogi, Daiichi Sankyo, Taisho, Dainippon Sumitomo, Taiho, Toyama Chemical, and Meiji Seika Pharma. Dr. Kohno has received honoraria from Taisho Toyama, Pfizer Japan, Astellas, Daiichi Sankyo, Shionogi, Dainippon Sumitomo, MSD, and Glaxo-SmithKline; manuscript fees from Taisho Toyama, Pfizer Japan, Astellas, Daiichi Sankyo, Shionogi, Dainippon Sumitomo, MSD, and GlaxoSmithKline; research funding from KYORIN, Pfizer, and Meiji Seika Kaisha; donations from MSD, Meiji Seika Kaisha, Daiichi
PY - 2012/8
Y1 - 2012/8
N2 - A survey on adult community-acquired pneumonia was conducted jointly by multiple centers nationwide to verify theJapanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults (JRS2005). The efficacyand safety of piperacillin (PIPC) were investigated at the same time. PIPC is recommended as the initial treatment forpatients with suspected bacterial pneumonia and pneumococcal pneumonia in JRS2005. Overall, 552 and 333 patients wereregistered for safety and efficacy analysis in this study, respectively. The majority of the cases in which PIPC was used hadmoderate disease (63.7 %), and the most common daily dosage was 4 g (73.6 %). The efficacy rate was 83.5 % overall, 81.1 % inpatients with suspected bacterial pneumonia, and 92.8 % in patients with pneumococcal pneumonia. The efficacy rate with adaily dosage of 4 g was 84.9 %, and the efficacy rates achieved with a daily dosage of 4 g in patients who had mild andmoderate suspected bacterial pneumonia were 90.0 and 82.6 %, respectively. The most commonly isolated causative organismswere Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. influenzae), and the bacterial eradication rateswere high (97.2 and 100 %, respectively). The incidence of adverse drug reactions was 5.62 %, among which the main eventswere hepatic dysfunction and decreased white blood cell count. In conclusion, this study showed that PIPC is safe andeffective at 4 g/day for mild-to-moderate adult community-acquired pneumonia.
AB - A survey on adult community-acquired pneumonia was conducted jointly by multiple centers nationwide to verify theJapanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults (JRS2005). The efficacyand safety of piperacillin (PIPC) were investigated at the same time. PIPC is recommended as the initial treatment forpatients with suspected bacterial pneumonia and pneumococcal pneumonia in JRS2005. Overall, 552 and 333 patients wereregistered for safety and efficacy analysis in this study, respectively. The majority of the cases in which PIPC was used hadmoderate disease (63.7 %), and the most common daily dosage was 4 g (73.6 %). The efficacy rate was 83.5 % overall, 81.1 % inpatients with suspected bacterial pneumonia, and 92.8 % in patients with pneumococcal pneumonia. The efficacy rate with adaily dosage of 4 g was 84.9 %, and the efficacy rates achieved with a daily dosage of 4 g in patients who had mild andmoderate suspected bacterial pneumonia were 90.0 and 82.6 %, respectively. The most commonly isolated causative organismswere Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. influenzae), and the bacterial eradication rateswere high (97.2 and 100 %, respectively). The incidence of adverse drug reactions was 5.62 %, among which the main eventswere hepatic dysfunction and decreased white blood cell count. In conclusion, this study showed that PIPC is safe andeffective at 4 g/day for mild-to-moderate adult community-acquired pneumonia.
KW - Clinical efficacy
KW - Community-acquired pneumonia
KW - Piperacillin
KW - Post-marketing surveillance
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84865131344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865131344&partnerID=8YFLogxK
U2 - 10.1007/s10156-012-0417-4
DO - 10.1007/s10156-012-0417-4
M3 - Article
C2 - 22618270
AN - SCOPUS:84865131344
VL - 18
SP - 544
EP - 551
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 4
ER -